JP2016014070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016014070A5 JP2016014070A5 JP2015207655A JP2015207655A JP2016014070A5 JP 2016014070 A5 JP2016014070 A5 JP 2016014070A5 JP 2015207655 A JP2015207655 A JP 2015207655A JP 2015207655 A JP2015207655 A JP 2015207655A JP 2016014070 A5 JP2016014070 A5 JP 2016014070A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- oligonucleotide decoy
- pain
- cell
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 10
- 108091034117 Oligonucleotide Proteins 0.000 claims 7
- 208000002193 Pain Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 210000002569 neuron Anatomy 0.000 claims 2
- 230000008055 nociceptive signaling Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 102100026865 Cyclin-dependent kinase 5 activator 1 Human genes 0.000 claims 1
- 102100027346 GTP cyclohydrolase 1 Human genes 0.000 claims 1
- 102000017679 HTR3A Human genes 0.000 claims 1
- 101000761343 Homo sapiens 5-hydroxytryptamine receptor 3A Proteins 0.000 claims 1
- 101000862581 Homo sapiens GTP cyclohydrolase 1 Proteins 0.000 claims 1
- 101001032845 Homo sapiens Metabotropic glutamate receptor 5 Proteins 0.000 claims 1
- 101001123678 Homo sapiens Phenylethanolamine N-methyltransferase Proteins 0.000 claims 1
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 claims 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 claims 1
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 claims 1
- 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 claims 1
- 102100024611 Phosphatidylethanolamine N-methyltransferase Human genes 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 108010064131 neuronal Cdk5 activator (p25-p35) Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91758307P | 2007-05-11 | 2007-05-11 | |
| US60/917,583 | 2007-05-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014149516A Division JP5890869B2 (ja) | 2007-05-11 | 2014-07-23 | 遺伝子発現と疼痛 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016064037A Division JP6306075B2 (ja) | 2007-05-11 | 2016-03-28 | 遺伝子発現と疼痛 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016014070A JP2016014070A (ja) | 2016-01-28 |
| JP2016014070A5 true JP2016014070A5 (cg-RX-API-DMAC7.html) | 2016-05-19 |
| JP6082796B2 JP6082796B2 (ja) | 2017-02-15 |
Family
ID=40002879
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010507728A Expired - Fee Related JP5646320B2 (ja) | 2007-05-11 | 2008-05-12 | 遺伝子発現と疼痛 |
| JP2014149516A Expired - Fee Related JP5890869B2 (ja) | 2007-05-11 | 2014-07-23 | 遺伝子発現と疼痛 |
| JP2015207655A Expired - Fee Related JP6082796B2 (ja) | 2007-05-11 | 2015-10-22 | 遺伝子発現と疼痛 |
| JP2016064037A Expired - Fee Related JP6306075B2 (ja) | 2007-05-11 | 2016-03-28 | 遺伝子発現と疼痛 |
| JP2017106521A Pending JP2017148074A (ja) | 2007-05-11 | 2017-05-30 | 遺伝子発現と疼痛 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010507728A Expired - Fee Related JP5646320B2 (ja) | 2007-05-11 | 2008-05-12 | 遺伝子発現と疼痛 |
| JP2014149516A Expired - Fee Related JP5890869B2 (ja) | 2007-05-11 | 2014-07-23 | 遺伝子発現と疼痛 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016064037A Expired - Fee Related JP6306075B2 (ja) | 2007-05-11 | 2016-03-28 | 遺伝子発現と疼痛 |
| JP2017106521A Pending JP2017148074A (ja) | 2007-05-11 | 2017-05-30 | 遺伝子発現と疼痛 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US7943591B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2818550B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP5646320B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008251320B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2723672C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2158316T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2542511T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20150759T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE025701T2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2158316T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2158316E (cg-RX-API-DMAC7.html) |
| SI (1) | SI2158316T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008141308A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2158316T3 (pl) | 2007-05-11 | 2015-10-30 | Adynxx Inc | Ekspresja genowa oraz ból |
| AU2009323766B2 (en) | 2008-12-02 | 2016-10-06 | Wave Life Sciences Ltd. | Method for the synthesis of phosphorus atom modified nucleic acids |
| SG177564A1 (en) | 2009-07-06 | 2012-02-28 | Ontorii Inc | Novel nucleic acid prodrugs and methods of use thereof |
| US8609617B2 (en) | 2009-09-04 | 2013-12-17 | University Of Miami | KLF family members regulate intrinsic axon regeneration ability |
| EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| CA2848740A1 (en) | 2011-09-16 | 2013-03-21 | Mingxing Wang | Amphiphilic cationic polymers for the delivery of therapeutic agents |
| US9139829B2 (en) * | 2012-02-28 | 2015-09-22 | Medical Diagnostic Laboratories, Llc | SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment |
| AU2013259402B2 (en) | 2012-05-10 | 2017-12-21 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
| JP6246121B2 (ja) | 2012-07-13 | 2017-12-13 | 株式会社新日本科学 | キラル核酸アジュバント |
| JP6268157B2 (ja) | 2012-07-13 | 2018-01-24 | 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ | 不斉補助基 |
| SG10201912895PA (en) | 2012-07-13 | 2020-02-27 | Wave Life Sciences Ltd | Chiral control |
| GB201310853D0 (en) * | 2013-06-18 | 2013-07-31 | Ucb Pharma Sa | Method |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| PT3094728T (pt) | 2014-01-16 | 2022-05-19 | Wave Life Sciences Ltd | Desenho quiral |
| EP3180434B1 (en) * | 2014-08-15 | 2019-07-17 | Adynxx, Inc. | Oligonucleotide decoys for the treatment of pain |
| JP6993230B2 (ja) * | 2015-09-09 | 2022-01-13 | アンジェス株式会社 | キメラデコイ |
| WO2017151644A1 (en) * | 2016-02-29 | 2017-09-08 | Adynxx, Inc. | Compositions and methods for pain amelioration via modification of gene expression |
| WO2024044770A1 (en) * | 2022-08-26 | 2024-02-29 | Core Biotherapeutics, Inc. | Oligonucleotides for the treatment of breast cancer |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410516B1 (en) * | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
| US5206152A (en) * | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| US5272056A (en) | 1991-01-03 | 1993-12-21 | The Research Foundation Of State University Of New York | Modification of DNA and oligonucleotides using metal complexes of polyaza ligands |
| EP0580754A1 (en) * | 1991-04-18 | 1994-02-02 | The Salk Institute For Biological Studies | Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences |
| FR2675803B1 (fr) | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
| EP0771320A4 (en) * | 1993-07-29 | 1998-11-25 | Univ California | POLYNUCLEOTIDE LURES INHIBITING THE EXPRESSION OF MAJOR II HISTOCOMPATIBILITY COMPLEX, AND APPLICATIONS |
| ATE395065T1 (de) * | 1993-10-29 | 2008-05-15 | Brigham & Womens Hospital | Therapeutische verwendung von cis-element-fallen in vivo |
| ATE295367T1 (de) | 1994-11-17 | 2005-05-15 | Taiho Pharmaceutical Co Ltd | Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält |
| AU5369396A (en) | 1995-03-23 | 1996-10-08 | Research Foundation Of The State University Of New York, The | Rest protein and dna |
| AU715125B2 (en) * | 1995-05-11 | 2000-01-20 | Merck Serono Sa | IL-6 activity inhibitor |
| ES2285712T3 (es) * | 1995-05-12 | 2007-11-16 | Anges Mg, Inc. | Medicamento para la terapia y profilaxis de varias enfermedades relacionadas con nf-kappa b. |
| GB9515356D0 (en) | 1995-07-26 | 1995-09-20 | Medical Res Council | Improvements in or relating to delivery of nucleic acid |
| US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
| CA2255822A1 (en) * | 1996-05-20 | 1997-11-27 | The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services | Oligonucleotides which specifically bind retroviral nucleocapsid proteins |
| US6022863A (en) * | 1996-05-21 | 2000-02-08 | Yale University | Regulation of gene expression |
| WO1999001155A1 (en) * | 1997-07-04 | 1999-01-14 | Fujisawa Pharmaceutical Co., Ltd. | Brain-protective agent |
| JP3667047B2 (ja) | 1997-09-12 | 2005-07-06 | キヤノン株式会社 | 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法 |
| US6376471B1 (en) | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
| US6060310A (en) * | 1997-11-24 | 2000-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Transcription factor decoy and tumor growth inhibitor |
| WO1999031115A1 (en) | 1997-12-16 | 1999-06-24 | The University Of Saskatchewan | Conductive metal-containing nucleic acids |
| NZ508505A (en) | 1998-06-02 | 2003-04-29 | Glaxo Group Ltd | Treatment of wounds using an Egr-1 transcription factor polypeptide |
| US6818626B1 (en) | 1998-07-17 | 2004-11-16 | Mirus Corporation | Chelating systems for use in the delivery of compounds to cells |
| US6867289B1 (en) * | 1998-10-26 | 2005-03-15 | Board Of Regents, The University Of Texas Systems | Thio-modified aptamer synthetic methods and compositions |
| US6008048A (en) * | 1998-12-04 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of EGR-1 expression |
| US7160869B2 (en) | 1998-12-16 | 2007-01-09 | University Of Saskatchewan | Biologically active metal-containing nucleic acids |
| ATE354667T1 (de) | 1998-12-23 | 2007-03-15 | Genentech Inc | Transfectaconen, die kalciumphosphat und eine nucleinsäure enthalten |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| US6333408B1 (en) * | 1999-03-08 | 2001-12-25 | Kureha Chemical Industry Co., Ltd. | Oligonucleotides inhibitors of PAI-1 MRNA |
| FR2790955B1 (fr) * | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| US6599741B1 (en) * | 1999-09-14 | 2003-07-29 | Avontec Gmbh | Modulating transcription of genes in vascular cells |
| US6927027B2 (en) | 1999-12-21 | 2005-08-09 | Ingeneus Corporation | Nucleic acid multiplex formation |
| US6969704B1 (en) * | 2000-08-25 | 2005-11-29 | The Trustees Of Columbia University In The City Of New York | Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject |
| DE10049549A1 (de) * | 2000-10-06 | 2002-05-02 | Markus Hecker | Modulation der Transkription pro-inflammatorischer Genprodukte |
| US20040192598A1 (en) | 2000-10-11 | 2004-09-30 | Laura Kragie | Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
| EP1344536A4 (en) | 2000-11-24 | 2005-01-19 | Chugai Pharmaceutical Co Ltd | METHOD FOR REGULATING THE ACTIVITY OF EXPRESSION OF A GENETIC PRODUCT TRANSFERRED INTO A LIVING ORGANISM |
| WO2002066071A2 (en) | 2001-01-03 | 2002-08-29 | Thomas Jefferson University | Treatment of tissue fibrosis by blocking the sp1 transcription factor |
| WO2002057480A2 (en) * | 2001-01-22 | 2002-07-25 | Genta Incorporated | Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers |
| PT1362600E (pt) | 2001-02-20 | 2008-07-09 | Anges Mg Inc | Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica |
| AU2002254132A1 (en) | 2001-03-06 | 2002-09-19 | Sierra Sciences, Inc. | Methods and compositions for modulating telomerase reverse transcriptase (tert) expression |
| US20030166555A1 (en) * | 2001-04-02 | 2003-09-04 | Alberini Cristina M. | Methods and compositions for regulating memory consolidation |
| EP1298141A1 (en) | 2001-09-27 | 2003-04-02 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Interleukin-4 (IL-4) promoter sequences specifically interacting with IRF-1 and IRF-2 |
| DE10148828B4 (de) * | 2001-10-04 | 2005-05-19 | Avontec Gmbh | Modulation der Expression STAT-1-abhängiger Gene |
| US6663880B1 (en) | 2001-11-30 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Permeabilizing reagents to increase drug delivery and a method of local delivery |
| JP2005519917A (ja) | 2002-02-01 | 2005-07-07 | オメロス コーポレイション | 軟骨分解の全身阻害のための組成物および方法 |
| CN1240439C (zh) | 2002-03-28 | 2006-02-08 | 南京凯基生物科技发展有限公司 | 肿瘤基因开关药物 |
| EP1499721B1 (en) | 2002-04-26 | 2013-05-29 | AnGes MG, Inc. | CIRCULAR DUMBBELL DECOY OLIGODEOXYNUCLEOTIDES (CDODN) CONTAINING DNA BINDINGS SITES FOR THE TRANSCRIPTION FACTOR NF-kappa B |
| DE10242319A1 (de) * | 2002-09-12 | 2004-03-25 | Avontec Gmbh | Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens |
| DE10257421A1 (de) * | 2002-12-09 | 2004-07-08 | Grünenthal GmbH | Regulatorische Elemente im 5'-Bereich des VR1-Gens |
| KR20110079741A (ko) | 2002-12-09 | 2011-07-07 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| US20050158733A1 (en) | 2003-06-30 | 2005-07-21 | Gerber David J. | EGR genes as targets for the diagnosis and treatment of schizophrenia |
| US20080233644A1 (en) * | 2003-09-12 | 2008-09-25 | Helen Fillmore | Chimeric Transcription Factor Decoy Oligonucleotides |
| JP2005336081A (ja) | 2004-05-26 | 2005-12-08 | Anges Mg Inc | Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤 |
| US7482158B2 (en) * | 2004-07-01 | 2009-01-27 | Mathison Brian H | Composite polynucleic acid therapeutics |
| WO2006012625A2 (en) * | 2004-07-22 | 2006-02-02 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Stat3 decoy oligonucleotides and uses therefor |
| WO2006034433A2 (en) * | 2004-09-21 | 2006-03-30 | Anesiva, Inc. | Delivery of polynucleotides |
| KR101357016B1 (ko) | 2004-09-28 | 2014-02-03 | 쿠아크 파마수티칼스 인코퍼레이티드 | 탈모증, 급성신부전증 및 다른 질환의 치료를 위한올리고리보뉴클레오티드 및 그것의 사용방법 |
| US8067384B2 (en) | 2004-10-22 | 2011-11-29 | Anges Mg, Inc. | Chimera (double) decoy |
| US7585848B2 (en) * | 2005-01-11 | 2009-09-08 | Rush University Medical Center | Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc |
| US8268572B2 (en) * | 2005-03-04 | 2012-09-18 | Dana-Farber Cancer Institute, Inc. | Methods to identify inhibitors of Runx1-mediated expression of nociceptive receptors and ion channels |
| US7680060B2 (en) * | 2005-03-08 | 2010-03-16 | Cisco Technology, Inc. | Transferring state information in a network |
| WO2006104913A2 (en) * | 2005-03-25 | 2006-10-05 | Medtronic, Inc. | USE OF ANTI-TNF OR ANTI-ILl RNAI TO SUPPRESS PRO- INFLAMMATORY CYTOKINE ACTIONS LOCALLY TO TREAT PAIN |
| JP2010505556A (ja) | 2006-10-09 | 2010-02-25 | ニューロフルーディクス， インコーポレイテッド | 脳脊髄液精製システム |
| US8808747B2 (en) | 2007-04-17 | 2014-08-19 | Baxter International Inc. | Nucleic acid microparticles for pulmonary delivery |
| PL2158316T3 (pl) * | 2007-05-11 | 2015-10-30 | Adynxx Inc | Ekspresja genowa oraz ból |
| SG187165A1 (en) | 2010-08-20 | 2013-02-28 | Replicor Inc | Oligonucleotide chelate complexes |
| EP2723865B1 (en) | 2011-06-21 | 2019-03-27 | Alnylam Pharmaceuticals, Inc. | METHODS FOR DETERMINING ACTIVITY OF RNAi IN A SUBJECT |
| DK2734212T3 (da) | 2011-07-20 | 2017-11-06 | Hospira Inc | Sammensætninger omfattende diclofenac til behandling af postoperativ smerte |
| AU2013259402B2 (en) | 2012-05-10 | 2017-12-21 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
| MY168778A (en) | 2012-05-18 | 2018-12-04 | Replicor Inc | Oligonucleotide chelate complex-polypeptide compositions and methods |
| EP3180434B1 (en) | 2014-08-15 | 2019-07-17 | Adynxx, Inc. | Oligonucleotide decoys for the treatment of pain |
| WO2017151644A1 (en) | 2016-02-29 | 2017-09-08 | Adynxx, Inc. | Compositions and methods for pain amelioration via modification of gene expression |
-
2008
- 2008-05-12 PL PL08755344T patent/PL2158316T3/pl unknown
- 2008-05-12 EP EP14179247.3A patent/EP2818550B1/en not_active Not-in-force
- 2008-05-12 SI SI200831461T patent/SI2158316T1/sl unknown
- 2008-05-12 AU AU2008251320A patent/AU2008251320B2/en not_active Ceased
- 2008-05-12 WO PCT/US2008/063471 patent/WO2008141308A2/en not_active Ceased
- 2008-05-12 US US12/119,435 patent/US7943591B2/en not_active Expired - Fee Related
- 2008-05-12 HR HRP20150759TT patent/HRP20150759T1/hr unknown
- 2008-05-12 HU HUE08755344A patent/HUE025701T2/en unknown
- 2008-05-12 ES ES08755344.2T patent/ES2542511T3/es active Active
- 2008-05-12 CA CA2723672A patent/CA2723672C/en active Active
- 2008-05-12 EP EP16199871.1A patent/EP3199635B1/en not_active Not-in-force
- 2008-05-12 ES ES14179247.3T patent/ES2619314T3/es active Active
- 2008-05-12 JP JP2010507728A patent/JP5646320B2/ja not_active Expired - Fee Related
- 2008-05-12 EP EP08755344.2A patent/EP2158316B1/en not_active Not-in-force
- 2008-05-12 PT PT87553442T patent/PT2158316E/pt unknown
- 2008-05-12 DK DK08755344.2T patent/DK2158316T3/en active
-
2011
- 2011-03-15 US US13/048,793 patent/US8093225B2/en not_active Expired - Fee Related
- 2011-12-09 US US13/316,321 patent/US8741864B2/en active Active - Reinstated
-
2014
- 2014-04-22 US US14/258,927 patent/US9290762B2/en not_active Expired - Fee Related
- 2014-07-23 JP JP2014149516A patent/JP5890869B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-22 JP JP2015207655A patent/JP6082796B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-09 US US15/019,791 patent/US10041069B2/en active Active
- 2016-03-28 JP JP2016064037A patent/JP6306075B2/ja not_active Expired - Fee Related
-
2017
- 2017-05-30 JP JP2017106521A patent/JP2017148074A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016014070A5 (cg-RX-API-DMAC7.html) | ||
| FI3618875T3 (fi) | Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito | |
| HRP20210819T1 (hr) | Fenfluramin za uporabu u liječenju dravet sindroma | |
| WO2016205410A3 (en) | Defined multi-conjugate oligonucleotides | |
| JP2016518337A5 (cg-RX-API-DMAC7.html) | ||
| JP2010526541A5 (cg-RX-API-DMAC7.html) | ||
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| EP4349820A3 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| JP2015517488A5 (cg-RX-API-DMAC7.html) | ||
| EA033457B1 (ru) | Способ лечения рака у пациентов с мутациями в генах ros1, ntrk1, ntrk2 и/или ntrk3 | |
| WO2017078499A3 (ko) | 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물 | |
| WO2016115543A3 (en) | Novel micro-dystrophins and related methods of use | |
| JP2012144574A5 (cg-RX-API-DMAC7.html) | ||
| JP2010059183A5 (cg-RX-API-DMAC7.html) | ||
| JP2017532343A5 (cg-RX-API-DMAC7.html) | ||
| RU2017116973A (ru) | Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса | |
| JP2016523260A5 (cg-RX-API-DMAC7.html) | ||
| RU2016150116A (ru) | Ингибитор пролиферации раковых стволовых клеток | |
| RU2015140572A (ru) | Способы лечения колоректального рака | |
| JP2016512817A5 (cg-RX-API-DMAC7.html) | ||
| WO2017106175A3 (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION | |
| EA201692392A1 (ru) | Новая лекарственная форма мелоксикама | |
| WO2019060522A3 (en) | Thiomorpholino oligonucleotides for the treatment of muscular dystrophy | |
| WO2016163799A3 (ko) | 2-메톡시-4-(3-(4-메톡시페닐)프로프-1-엔-1-일)페놀을 유효성분으로 하는 암의 치료용 약제학적 조성물 | |
| JP2017529834A5 (cg-RX-API-DMAC7.html) |